GeneDx Third Quarter 2026 Earnings Conference Call - GENEDX HOLDINGS CORP

Explicit Guidance:

• Full-Year 2026: Revenue reaffirmed at $475M–$490M (expecting the low end); Adjusted gross margin raised to ~71%; Adjusted net income raised to ≥$12M; Exome and genome volume growth adjusted to 28% (reflecting a 2026 volume CAGR of ~28%); Exome and genome revenue growth adjusted to ~17%.
• Q4 2026: Total revenue guidance of ~$135M; Exome and genome revenue of $121M (implying a ~2.5M test volume); Total test volume of 34,500 tests; Adjusted gross margin ≥71%; Adjusted net income ~$12M; Average Reimbursement Rate (ARR) guidance to ~$3,500/test.
• FY2027: No formal financial guidance provided; Expect mid-single-digit headwind to 2027 revenue from PAMA exposure (approx. 45% of revenue subject to CLFS), which management expects will be fully offset by RCM improvements and cost reductions.

Business-Segment Outlook:

• Volume/Trajectory: 2026 foundational volume growth expected to end in the "high 20s" (down from previous high 30s due to RCM documentation frictions); 2027 expected to see a return to high-volume growth rates as collection improvements converge with volume.
• Product Mix: Outpatient genome mix reduced to 26% (from 32% in Q2) for near-term unit economics; Expect genome mix to rise again in 2027 as collection rates improve and cost per test decreases; Long-read sequencing to be included in the portfolio with a launch in the coming quarters.
• Geographic/Clinical Segments: General pediatricians (GenPeds) identified as the largest single growth driver in 2027; NICU and Prenatal markets growing faster than the overall company but require programmatic execution and guideline updates; GenPeds commercial team already paying for itself.
• Unit Economics: Genome COGS reduced 43% YoY with an expected continued downward trajectory; Target to reduce genome COGS by "a few hundred dollars" over the next several quarters; Exome COGS relatively flat/near parity on dry-side steps; Goal to normalize the COGS gap via reagent cost reductions and AI-driven efficiency.

Market and Competitive Outlook:

• Demand Trends: Demand remains strong (accessions grew 28% YoY); Market leader position maintained with "no slowdown" of demand anticipated for 2026/2027.
• Payer Dynamics: Exome coverage at 98% of commercial lives; Genome coverage at 88% of commercial lives; Medicaid exome coverage in 37 states (up from 32% in Q2); Genome coverage in 25 states (up from 23 in Q2); Carillon policy (56M lives) expected to drive incremental revenue in 2027 as operationalization completes.
• Competitive Landscape: Management views competition as a catalyst to change the "status quo" of low utilization; No observed shift in competitive behavior in Q3; Belief that "Genome" will become the standard for diagnosing heritable disease.
• Data Asset: GDX Infinity (biopharma/data business) growing for a second consecutive quarter; New partners added (Mirum, Barron Therapeutics); Increasing interest from AI/Tech players for drug discovery/precision medicine applications.

Macro / Industry Outlook:

• PAMA/CLFS: Approximately 45% of revenue exposed to PAMA (percentage of CLFS); 45% of revenue insulated via negotiated discrete fee schedules (1–3 year renewal cycle); PAMA impact expected to be a mid-single-digit headwind in 2027.
• Economy: No specific macroeconomic headwinds cited; Focus on structural changes in payer coverage (Medicaid expansion) and operational efficiency as primary economic drivers.
• Regulation/Policy: Active work to update prenatal guidelines (currently lagging) to capture CMA testing displacement; Medicaid expansion in additional states expected to be a foundational catalyst for 2027.

Strategic Initiatives:

• RCM Transformation: Multi-year revenue cycle transformation in early stages; Q3 focused on validating plan and new leadership; Q4 and early 2027 focused on implementation and "pull-through"; AI/ML tools to be deployed to automate payer-specific documentation collection.
• Commercial Expansion: GenPeds team entered field in February; Salesforce expansion planned for 2027 but at a more incremental pace than 2026 (no major "big bet" like AAP guidelines without similar catalysts); Continued investment in EHR connectivity (Epic Aura) to improve user experience and documentation capture.
• Technology: Launch of Long-Read/Long-Range sequencing in Q4/2027; Continued investment in "GDX Infinity" data asset to enhance interpretation of de novo variants.
• Personnel: Appointment of Nicole Masson as Chief Patient Access Officer to drive payer partnerships and government relations.
• Timing: RCM improvements (collection rate uplift) expected to significantly impact financials in 2027 and beyond; Volume "catch-up" expected over time as pre-analytical workflows digitize and accelerate.

Risks and Headwinds to Outlook:

• Volume Friction: Near-term volume headwind (25% reported growth vs. 28% accession growth) caused by stricter upfront documentation requirements; 3% of accessions resulted in cancellations/downgrades/delays.
• Payer Operational Lag: Positive coverage policies (e.g., Carillon, state Medicaid expansions) are slow to operationalize; Impact on collections and volume is gradual.
• Clinical Necessity: 38% of denials relate to subjective clinical necessity disputes or uncovered patients; Management acknowledges this is a "justice issue" but prioritizes paid volume for sustainability.
• Cost Pressures: Genome COGS remains significantly higher than exome; Reagent cost reductions are necessary to close the gap.
• Regulatory Exposure: PAMA implementation remains a mid-single-digit revenue headwind for 2027.
• Seasonality: Q1 2027 expected to remain seasonally low; Q4 typically strongest.

Management Tone on the Future:

• Confidence Level: High confidence in "durable revenue growth" and "profitable execution"; View of long-term market opportunity remains unchanged.
• Strategic Pivot: Deliberately prioritizing "paid volume" over "volume at all costs" to ensure a self-sustaining business model; Willing to accept near-term volume friction (delays/cancellations) to secure reimbursement.
• Guidance Changes: Raised margins and net income; Reaffirmed top-line revenue; Adjusted volume guidance downward for 2026 to reflect operational discipline.
• Outlook: "Positive trajectory to end this year and enter into 2027"; Expect revenue growth rates to converge closer to high volume growth rates in 2027.

Miscellaneous:

• New Leadership: New Chief Patient Access Officer (Nicole Masson) and RCM leadership teams in place to execute multi-year transformation.
• Product Innovation: New ordering features, simplified reports, and post-test guides released to aid adoption; Long-range sequencing to be added to portfolio.
• Data Utilization: GDX Infinity data is being leveraged to confirm genetic diagnoses by matching patient profiles, creating a cumulative competitive moat.